Legal & General Group Plc acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 359,499 shares of the biotechnology company’s stock, valued at approximately $19,560,000. Legal & General Group Plc owned 0.15% of Exelixis at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of EXEL. Motiv8 Investments LLC bought a new position in Exelixis in the 4th quarter worth $26,000. Cassaday & Co Wealth Management LLC bought a new stake in Exelixis during the first quarter valued at about $27,000. Acumen Wealth Advisors LLC bought a new stake in Exelixis during the fourth quarter valued at about $29,000. Western Wealth Management LLC purchased a new position in shares of Exelixis in the first quarter valued at about $29,000. Finally, Activest Wealth Management purchased a new position in shares of Exelixis in the fourth quarter valued at about $32,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.
More Exelixis News
Here are the key news stories impacting Exelixis this week:
- Positive Sentiment: Strong sales and earnings, along with reported institutional support, have helped Exelixis shares gain 43.5% over the past year. The company’s latest reported quarter also showed adjusted earnings of $0.91 per share, ahead of the $0.85 consensus estimate, while revenue increased 10.6% year over year. Strong Sales, Earnings Send Exelixis Shares Higher
- Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $3.18 from $3.12 and increased its Q1 2027 estimate to $0.80 from $0.79. It also lifted its Q3 2027 forecast slightly to $0.93 from $0.92, suggesting some confidence in near-term earnings execution.
- Neutral Sentiment: Exelixis remains near its 52-week high, with shares recently trading around $54.45 versus a high of $57.57. Its valuation is approximately 17 times earnings, while the company continues to show strong profitability, including a reported 35.3% net margin and 42.2% return on equity.
- Negative Sentiment: Zacks Research maintains a “Strong Sell” rating and made several downward revisions: FY2027 EPS fell to $3.57 from $3.60, Q2 2027 EPS declined to $0.84 from $0.89, Q4 2026 EPS decreased to $0.81 from $0.83, and Q1 2028 EPS edged down to $0.96 from $0.97. These cuts could pressure the stock despite the modest upward revisions elsewhere.
- Negative Sentiment: Options activity was unusually bearish on August 27, with traders purchasing 10,010 put contracts—about 826% above the average daily put volume of 1,081. The surge indicates increased demand for downside protection or speculation on a decline.
Exelixis Trading Down 1.5%
Exelixis (NASDAQ:EXEL – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. The business had revenue of $628.69 million for the quarter, compared to the consensus estimate of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The company’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 EPS. On average, research analysts forecast that Exelixis, Inc. will post 3.19 earnings per share for the current year.
Insider Activity at Exelixis
In other Exelixis news, Director Mary C. Beckerle sold 9,812 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the transaction, the director owned 16,079 shares in the company, valued at $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack L. Wyszomierski sold 3,925 shares of Exelixis stock in a transaction on Monday, June 1st. The stock was sold at an average price of $50.55, for a total transaction of $198,408.75. Following the completion of the transaction, the director directly owned 284,384 shares of the company’s stock, valued at $14,375,611.20. The trade was a 1.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 23,549 shares of company stock valued at $1,216,894. 2.60% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the company. Citigroup reiterated a “market outperform” rating on shares of Exelixis in a research report on Wednesday, July 22nd. HC Wainwright reissued a “buy” rating and issued a $56.00 price target on shares of Exelixis in a report on Thursday, July 2nd. Zacks Research downgraded Exelixis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. Citizens Jmp increased their price objective on shares of Exelixis from $50.00 to $55.00 and gave the company a “market outperform” rating in a report on Wednesday, June 24th. Finally, Royal Bank Of Canada lifted their price objective on shares of Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $50.07.
View Our Latest Stock Analysis on EXEL
About Exelixis
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
Featured Articles
- Five stocks we like better than Exelixis
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
